Loading
A phase 2 trial of Durvalumab in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.
Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE) is a phase 2 interventional study registered as NCT05925530 by AstraZeneca, with 142 participants enrolled, started 2024-02-22 and due to reach its primary completion in 2026-01-12. Interventions recorded: Durvalumab. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Resectable stage I to III non-small-cell lung cancer, Durvalumab, AstraZeneca, Immune checkpoint inhibitors.
Shares Resectable stage I to III non-small-cell lung cancer, Durvalumab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Durvalumab, AstraZeneca, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Durvalumab, AstraZeneca, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Resectable stage I to III non-small-cell lung cancer, AstraZeneca, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Durvalumab, AstraZeneca, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares Resectable stage I to III non-small-cell lung cancer, Small-cell lung cancer, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares Resectable stage I to III non-small-cell lung cancer, Durvalumab, Immune checkpoint inhibitors.